The heat is on Gilead as Tropics readout nears
Trodelvy has a chance to score in a study designed to expand its use, but given Gilead’s R&D track record nothing is certain.
Esmo Breast Cancer – Astra and Daiichi square up to Gilead
Datopotamab, a project with a very similar mechanism to Trodelvy, shows impressive early data in triple-negative breast cancer.
Another Astra-Daiichi tie-up puts Trop2 in focus
The UK big pharma is set to hand Japan’s Daiichi $1bn for rights to a second antibody-drug conjugate. Immunomedics watch out.
Pharma news over the Christmas period 2019
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
